Abcam, ab250581, Anti-LYAR antibody [EPR14352-9] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal LYAR antibody. Carrier free. Suitable for ICC/IF, IP, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14352-9,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:ICC/IF, WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250581 is the carrier-free version of
ab182138
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Lyar also known as the cell growth-regulating nucleolar protein is a zinc finger protein with a molecular mass of approximately 36 kDa. This protein is expressed primarily in the nucleolus although it can also be found in other sub-nuclear structures. Lyar binds to nucleic acids and proteins playing roles in nucleolus-related processes. Its expression is seen in various tissues but it is most pronounced in rapidly dividing cells such as those in fetal tissues and certain cancers.
Biological function summary
The Lyar protein plays a role in regulating cell growth and proliferation. It participates in ribosome biogenesis by interacting with pre-ribosomal RNA possibly aiding in the stabilization and processing of rRNA precursors. Lyar is not usually considered as part of a protein complex but its interactions with several other nucleolar proteins imply its involvement in complex regulatory networks. It influences the transcription of ribosomal RNA genes impacting protein synthesis rates and cell cycle progression.
Pathways
Lyar is involved in the modulation of pathways linked to cell proliferation and survival. Notably it affects the PI3K/AKT signaling pathway by interacting with nucleophosmin (NPM1) impacting cell growth and survival mechanisms. This collaboration can alter the response of cells to external growth signals influencing cellular responses to metabolic changes and stress.
Aberrant Lyar levels have been implicated in oncogenesis. Its overexpression has been noted in various cancers including leukemia and neuroblastoma linking it to uncontrolled cell division and tumor progression. In cancer Lyar interacts with tumorigenesis-associated proteins such as c-Myc enhancing their transcriptional activity and contributing to cancerous transformation. Understanding the role of Lyar in these disease processes remains essential for identifying potential therapeutic strategies and developing targeted interventions.